Biocon Biologics Enters Deal to Sell Dermatology and Nephrology Units

Biocon Biologics, a subsidiary of Biocon, has entered into a definitive agreement with Eris

India to Dominate Global Phama Markets by R&D Endeavours

The Indian pharmaceutical industry is poised to establish a robust presence in both domestic and

Huma Partners with Merck KGaA to Develops Cancer Treatment

Huma Therapeutics (Huma) and Merck KGaA, Darmstadt, Germany has collaborated to create a digital solution

Lupin introduces Rocuronium Bromide Injection in US Markets

Global pharmaceutical giant Lupin Limited (Lupin), following Lupin's alliance partner Caplin Steriles

Government to Offer Support for Treatment of Rare Diseases

The government is likely to before long come up with a component for giving treatment back to patients enduring

UK MHRA Authorized New Therapy for the Treatment of Breast Cancer

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) have approved this new

Lupin Get US FDA Nod for Generic Invokamet XR Tablets

Lupin Limited, a global pharmaceutical company, has received tentative approval from the FDA

MaaT Pharma Patient Dosing Phase 2b Trial for Blood Cancer

MaaT Pharma, a clinical-stage biotech firm, has recently disclosed the commencement of its phase

Nephron and NRx Pharma to Jointly Develop Treatment for Depression

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, while Nephron

Glenmark Get ANDA Nod for Fluphenazine Hydrochloride Tablets

Glenmark Pharmaceuticals has achieved the ultimate endorsement from the United States Food and Drug Administration (USFDA)

© 2025 India Pharma Outlook. All Rights Reserved.